𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of continuous subcutaneous interferon-alfa combined with cisplatin in advanced malignant melanoma

✍ Scribed by Richner, J; Joss, R.A; Goldhirsch, A; Brunner, K.W

Book ID
122548627
Publisher
Elsevier Science
Year
1992
Tongue
English
Weight
541 KB
Volume
28
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Recombinant interferon alfa-2a in advanc
Recombinant interferon alfa-2a in advanced malignant melanoma. a phase i-ii study in combination with dtic
✍ G. R. C. McLeod; D. B. Thomson; P. Hersey πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 French βš– 384 KB

There is a rising incidence of malignant melanoma world-wide and, despite major improvements in i t s early diagnosis and treatment, the 10-year death rate remains at 20-25%. Evidence that the immune system has a role in the control of melanoma growth has encouraged immunological intervention. The r

Interferon in combination with vinblasti
Interferon in combination with vinblastine in advanced malignant melanoma. A phase I–II study
✍ Stein Gundersen; A. Flokkmann πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 288 KB πŸ‘ 2 views

Nineteen patients with advanced malignant melanoma were treated with a combination of recombinant alfa-interferon (a-IFN) and vinblastine (VBL). The a-IFN was administered subcutaneously daily at an initial dose of 3 X lo6 IU escalating to a maximal dose of 9 X lo6 U daily for the first 10 weeks fol